CHAPEL HILL, NC -- (Marketwired) -- 09/04/13 -- Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, today announced the partial exercise of the over-allotment option granted to the underwriters to purchase an additional 100,000 shares of its common stock, at a price to the public of $10.00 per share. The overallotment option was granted in connection with the Company's recently announced underwritten public offering of 2,500,000 shares of common stock. The underwriters previously exercised their option to purchase 100,000 shares of common stock of the Company. The total gross proceeds to the Company from the offering, including the underwriters' exercise of their over-allotment option, to be received will be $27,000,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.
Aegis Capital Corp. acted as sole book-running manager for the offering.
Cantor Fitzgerald & Co. acted as a co-manager for the offering.
This offering was made only by means of a prospectus. Copies of the prospectus relating to this offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, New York 10019, telephone: 212-813-1010, e-mail: email@example.com.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 23, 2013. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Heat Biologics:
Heat Biologics (www.heatbio.com) is a clinical-stage biopharmaceutical company focused on developing its novel off-the-shelf ImPACT therapeutic vaccines to combat a wide range of cancers. Our proprietary ImPACT Therapy is being designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to "pump out" a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called "gp96" to educate and activate a cancer patient's immune system to recognize and kill cancerous cells. Heat shock protein gp-96 is a chaperone protein found in all human cells. Heat's lead compound, HS-110, will be entering Phase 2 trials against non-small cell lung cancer and its second product candidate, HS-410 will be entering Phase 1/2 clinical trials against bladder cancer.
|Heat Biologics, Inc. Announces Partial Exercise of Underwriters' Over-Allotment Option (2013/8/13)|
|RMG Networks Holding Corp. Announces Partial Exercise of Underwriters' Over-Allotment Option ()|
|InterCloud Systems, Inc. Announces Full Exercise of Underwriter's Over-Allotment Option (2013/11/15)|
|Blackstone Mortgage Trust, Inc. Announces Full Exercise Of Underwriters' Over-Allotment Option And Issuance Of Additional Convertible Senior Notes (2013/11/27)|
|Whitestone REIT Announces Full Exercise of Underwriters’ Over-Allotment Option to Purchase Additional Shares (2013/10/28)|
|Evoke Pharma Announces Full Exercise of Underwriters' Over-Allotment Option (2013/10/3)|
|Applied Optoelectronics Announces Full Exercise of Underwriters' Over-Allotment Option (2013/10/23)|
|NeoStem Announces Full Exercise of Underwriters' Over-Allotment Option (2013/10/8)|
|Independent Bank Corporation Announces Full Exercise Of Underwriters' Over-Allotment Option ()|
|Synthetic Biologics Announces Exercise of Underwriters' Over-Allotment Option (2013/12/13)|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.